Researchers in the Schools of Medicine and Engineering at Vanderbilt University have discovered a proteomic “signature” from the airways of heavy smokers that could lead to better risk assessment and perhaps new ways to stop lung cancer before it starts.
In the continuing evolution of personalized medicine, a new Yale study has found evidence to support the value of a tool that measures the presence of cancer-derived molecules in the blood of patients with lung cancer years after their treatment.
